Live
FierceBiotechAs Akeso takes center stage at ASCO, China biotech industry cements its coming of ageFierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune system10x Genomics NewsDeutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating - marketscreener.comFierceBiotechAscidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseasesEndpoints NewsLilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesBioPharma DiveLilly, Ascidian link up in RNA exon editing pactCellPlant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorinsCellExplosive cytotoxicity of ruptoblasts bridges hormone surveillance and immune defenseLabiotechSurge in M&As driven by patent expirationsThermo FisherThermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate Drug Discovery - BioSpectrum AsiaeLifeHSD17B7 is required for the function of sensory hair cells by regulating cholesterol synthesisBioPharma DiveCelcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Endpoints News Mar 4, 2026

Blackstone to support Teva on Sanofi-partnered TL1A with $400M

Blackstone to support Teva on Sanofi-partnered TL1A with $400M

Original
Body unavailable. Use the original source.